Osteoarthritis affects the majority of cats over 12 years, making it the most prevalent chronic pain condition in the feline population. Modern targeted therapies have transformed treatment options.
Studies using video gait analysis and radiography find osteoarthritis in over 90% of cats over 12 years and approximately 33% of cats overall. Despite this prevalence, feline OA remains dramatically undertreated—owners normalise mobility changes as "getting old" rather than recognising treatable pain. The Feline Grimace Scale, HHHHHMM quality of life scale, and validated owner questionnaires provide tools for systematic pain recognition and monitoring.
Bedinvetmab (Solensia/Librela for cats) is a monoclonal antibody targeting nerve growth factor (NGF), a key pain sensitisation mediator in osteoarthritis. Monthly subcutaneous injections have demonstrated significant pain reduction and improved mobility in clinical trials. As a species-specific feline antibody without NSAID-related adverse effects, it represents the most significant advance in feline OA management—enabling effective long-term analgesia where NSAIDs were previously the only option with cats' limited tolerance for long-term NSAID use.
Environmental adaptations reduce daily pain burden: ramps to elevated resting spots; low-sided litter trays enabling comfortable access; raised food and water bowls reducing neck flexion; heated beds; non-slip surfaces; and provision of resting spots at multiple heights allowing choice without painful jumping. These modifications are welfare-positive and cost-effective compared to pharmaceutical interventions alone.
Optimal feline OA management combines targeted analgesia with environmental modification, weight management (reducing joint loading), and supportive measures. Physiotherapy adapted for cats—passive range of motion exercises, gentle massage—can be taught to owners for home implementation. Omega-3 fatty acid supplementation reduces inflammatory mediators. Regular monitoring every 3-6 months using validated pain scales tracks treatment response and guides dose adjustments.